Department of Clinical Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, National Human Genetic Resources Sharing Service Platform, Tianjin, 300060, P. R. China.
Department of Immunology, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Educational Ministry of China, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, 300070, P. R. China.
Cancer Commun (Lond). 2020 Sep;40(9):435-452. doi: 10.1002/cac2.12076. Epub 2020 Jul 28.
Hypoxia is a hallmark of cancer and is associated with poor prognosis. However, the molecular mechanism by which hypoxia promotes tumor progression remains unclear. MicroRNAs dysregulation has been shown to play a critical role in the tumor and tumor microenvironment. Here, we investigated the roles of miR-495 and miR-5688 in human non-small cell lung cancer (NSCLC) and their underlying mechanism.
The expression levels of miR-495 and miR-5688 in human NSCLC tissue specimens were measured by quantitative real-time polymerase chain reaction (qRT-PCR). Deferoxamine (DFO) was used to determine whether the regulation of miR-495 and miR-5688 under hypoxia was dependent on hypoxia-inducible factor 1-alpha (HIF-1α). Furthermore, the functions of miR-495 and miR-5688 in tumor progression were evaluated using colony formation, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS), wound healing, transwell assays, and xenograft model. Two algorithms, PicTAR and Targetscan, were used to predict the target gene of these two miRNAs, and dual-luciferase reporter assay was conducted to confirm the target. The unpaired two-tailed t test, Pearson correlation analysis, and Fisher's exact probability test were performed for statistical analyses.
Two miRNAs, miR-495 and miR-5688, were found to participate in NSCLC progression under hypoxia. They were down-regulated in NSCLC tissues compared with normal tissues. We determined that hypoxia led to the down-regulation of miR-495 and miR-5688 in NSCLC cells, which was independent of HIF-1α and cellular metabolic energy. In addition, miR-495 and miR-5688 suppressed cell proliferation, migration, and invasion in vitro. The NSCLC xenograft model showed that miR-495 and miR-5688 inhibited tumor formation in vivo. Interestingly, we found that miR-495 and miR-5688 had the same target, interleukin-11 (IL-11). Recombinant human IL-11 counteracted the effects of miR-495 and miR-5688 on NSCLC cells, suggesting that miR-495 and miR-5688 executed their tumor suppressive role by repressing IL-11 expression.
We found that hypoxia down-regulated the expression levels of miR-495 and miR-5688 in NSCLC to enhance IL-11 expression and tumor progression, indicating that the miR-495/miR-5688/IL-11 axis may serve as a therapeutic target and potential biomarker for NSCLC.
缺氧是癌症的一个标志,与预后不良有关。然而,缺氧促进肿瘤进展的分子机制尚不清楚。microRNA 失调已被证明在肿瘤和肿瘤微环境中发挥关键作用。在这里,我们研究了 miR-495 和 miR-5688 在人类非小细胞肺癌 (NSCLC) 中的作用及其潜在机制。
通过实时定量聚合酶链反应 (qRT-PCR) 测量人非小细胞肺癌组织标本中 miR-495 和 miR-5688 的表达水平。使用去铁胺 (DFO) 来确定缺氧下 miR-495 和 miR-5688 的调节是否依赖于缺氧诱导因子 1-α (HIF-1α)。此外,使用集落形成、3-(4,5-二甲基噻唑-2-基)-5-(3-羧基甲氧基苯基)-2-(4-磺苯基)-2H-四唑 (MTS)、划痕愈合、transwell 测定和异种移植模型评估 miR-495 和 miR-5688 在肿瘤进展中的功能。使用两种算法,PicTAR 和 Targetscan,预测这两种 miRNA 的靶基因,并通过双荧光素酶报告基因检测证实靶基因。进行了配对双尾 t 检验、Pearson 相关分析和 Fisher 确切概率检验进行统计分析。
发现两种 miRNA,miR-495 和 miR-5688,在缺氧条件下参与 NSCLC 进展。与正常组织相比,它们在 NSCLC 组织中下调。我们确定缺氧导致 NSCLC 细胞中 miR-495 和 miR-5688 的下调,这与 HIF-1α和细胞代谢能量无关。此外,miR-495 和 miR-5688 抑制了体外细胞增殖、迁移和侵袭。NSCLC 异种移植模型表明 miR-495 和 miR-5688 在体内抑制肿瘤形成。有趣的是,我们发现 miR-495 和 miR-5688 具有相同的靶标白细胞介素 11 (IL-11)。重组人白细胞介素 11 (rhIL-11) 抵消了 miR-495 和 miR-5688 对 NSCLC 细胞的作用,表明 miR-495 和 miR-5688 通过抑制 IL-11 的表达来发挥其肿瘤抑制作用。
我们发现缺氧下调 NSCLC 中 miR-495 和 miR-5688 的表达水平,以增强 IL-11 的表达和肿瘤进展,表明 miR-495/miR-5688/IL-11 轴可能作为 NSCLC 的治疗靶点和潜在的生物标志物。